FY2025 Earnings Estimate for IPSC Issued By Leerink Partnrs

Century Therapeutics, Inc. (NASDAQ:IPSC) – Analysts at Leerink Partnrs issued their FY2025 earnings per share estimates for shares of Century Therapeutics in a research report issued to clients and investors on Monday, November 17th. Leerink Partnrs analyst D. Graybosch forecasts that the company will post earnings per share of ($0.06) for the year. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Century Therapeutics’ current full-year earnings is ($1.61) per share. Leerink Partnrs also issued estimates for Century Therapeutics’ Q4 2025 earnings at ($0.25) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.82) EPS, FY2027 earnings at ($0.78) EPS, FY2028 earnings at ($0.57) EPS and FY2029 earnings at ($0.45) EPS.

Century Therapeutics (NASDAQ:IPSC) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.07. Century Therapeutics had a negative return on equity of 10.01% and a negative net margin of 19.10%.

Other equities research analysts also recently issued research reports about the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Century Therapeutics in a research report on Wednesday, October 8th. Leerink Partners reiterated a “market perform” rating and set a $2.00 target price (down previously from $7.00) on shares of Century Therapeutics in a report on Monday. Finally, Wall Street Zen downgraded Century Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, October 20th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Century Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $3.40.

Century Therapeutics Stock Performance

Shares of IPSC stock opened at $0.49 on Wednesday. Century Therapeutics has a 52 week low of $0.34 and a 52 week high of $1.83. The company’s 50 day moving average price is $0.54 and its two-hundred day moving average price is $0.55. The company has a market capitalization of $42.78 million, a P/E ratio of -1.53 and a beta of 1.80.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC raised its stake in shares of Century Therapeutics by 64.1% during the 3rd quarter. Citadel Advisors LLC now owns 360,825 shares of the company’s stock worth $180,000 after purchasing an additional 140,891 shares in the last quarter. Two Sigma Investments LP raised its position in Century Therapeutics by 59.2% during the third quarter. Two Sigma Investments LP now owns 911,446 shares of the company’s stock worth $454,000 after acquiring an additional 338,902 shares in the last quarter. Squarepoint Ops LLC raised its position in Century Therapeutics by 483.1% during the third quarter. Squarepoint Ops LLC now owns 236,053 shares of the company’s stock worth $118,000 after acquiring an additional 195,573 shares in the last quarter. GSA Capital Partners LLP lifted its stake in Century Therapeutics by 29.3% in the third quarter. GSA Capital Partners LLP now owns 603,479 shares of the company’s stock valued at $301,000 after acquiring an additional 136,873 shares during the last quarter. Finally, Jane Street Group LLC bought a new position in shares of Century Therapeutics in the 2nd quarter valued at about $248,000. 50.20% of the stock is currently owned by institutional investors.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.